Status:
TERMINATED
The Efficacy and Safety of Escitalopram for Depression in Multiple Sclerosis
Lead Sponsor:
Weill Medical College of Cornell University
Collaborating Sponsors:
Forest Laboratories
Conditions:
Depression
Multiple Sclerosis
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Emotionally labile, depressed participants with multiple sclerosis treated with escitalopram will have a greater reduction in emotional lability scores and in their psychological distress scores than ...
Detailed Description
Patients with multiple sclerosis who are experiencing mood lability and symptoms of depression will be randomized to receive either escitalopram 10mg/day or placebo tablets for a period of 6 weeks. It...
Eligibility Criteria
Inclusion
- Clinical diagnosis of multiple sclerosis
- Having mild to moderate depressive symptoms, with or without emotional lability
- Experiencing psychological distress
Exclusion
- Meeting DSM-IV diagnostic criteria for Major Depressive Disorder or another Axis 1 diagnosis
- Cognitive impairment
- The presence of an unstable medical illness that might preclude completion of the study -
Key Trial Info
Start Date :
November 1 2004
Trial Type :
INTERVENTIONAL
End Date :
October 1 2006
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00151294
Start Date
November 1 2004
End Date
October 1 2006
Last Update
September 14 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
NewYork Presbyterian Hospital
White Plains, New York, United States, 10605